Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 9/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 4/20 | 0.48 |
| ▸ | MMP2 | P08253 | 8/20 | 0.47 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619409 | 0.92 | MMP2 (0.54) | BMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL8358421 | 0.91 | BMP1 (0.54) | BMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL12619403 | 0.89 | BMP1 (0.61) | BMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL8358332 | 0.82 | MMP2 (0.47) | BMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL27734963 | 0.81 | BMP1 (0.52) | BMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL1801064 | 0.81 | MMP2 (0.49) | BMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL12619398 | 0.81 | BMP1 (0.41) | BMP1MMP9MMP2ADAMTS4MMP1 | |
| SCHEMBL1799177 | 0.78 | BMP1 (0.58) | BMP1MMP9MMP13MMP2MMP3 | |
| Methyl P-Toluenesulfonyl-L-Argininate SCHEMBL2853451 | 0.76 | ITGB3 (0.57) | BMP1MMP9MMP2 | |
| Methyl P-Toluenesulfonyl-L-Argininate SCHEMBL324561 | 0.76 | ITGB3 (0.57) | BMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | BMP1 2810/4885MMP9 82/4885MMP13 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.